GOG GYN-LIVE

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy

This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.

We are pleased to share that the video recording for the GOG-3133 FRAmework-01 clinical trial is now available for on‑demand viewing.

In this video, Dr. Roisin O'Cearbhaill and Dr. Bhavana Pothuri provide a high-level overview of the study, including the scientific rationale, trial design, and key features of the three cohorts evaluating patients with platinum-resistant and platinum-sensitive ovarian cancer. 

We encourage all investigators and research staff involved with GOG-3133 to review the video and share it with members of their study teams. The video is intended to support understanding of the study and prepare sites for successful patient identification and enrollment.

Thank you for your continued dedication to advancing ovarian cancer research. If you have any questions about the study, please reach out to the GOG-3133 study team.

Contact Study PIs:

Roisin O'Cearbhaill, MD

Memorial Sloan Kettering Cancer Center

[email protected]

Bhavana Pothuri, MD

NYU Langone

[email protected]

The GOG Foundation, Inc. would like to thank our commercial supporters for their support of the GOG GYN-LIVE Podcast:
Corcept Therapeutics, GSK, Pfizer Oncology, Eli Lilly, Genmab, and Verastem

In this episode, we dive into GOG‑3101 TroFuse‑20—a Phase 3, randomized, active‑controlled, open‑label, multicenter study evaluating MK‑2870 monotherapy versus Treatment of Physician’s Choice as second‑ or third‑line therapy for patients with recurrent or metastatic cervical cancer.

The GOG Foundation, Inc. and GOG Partners are thrilled to present the “The GOG Highlight Reel”, an ongoing Education Series that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year.  

The GOG Highlight Reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course examines recent clinical trial data in gynecologic malignancies, offering insights on data presentations, ongoing research, and drug approvals shaping the field. It addresses common gynecologic malignancies, aiding physicians in comprehending the evolving treatment landscape, including understanding trials in progress. Participants will receive a synthesis of recent studies and explore key components of clinical trials, gaining essential knowledge for research in these malignancies. Dynamic discussions will focus on emerging approved therapies and investigational agents, with an intent to provide insights into current (as well as future) advancements. Join us for a journey through clinical trials in ovarian, endometrial and cervical cancers, gaining the skills to navigate the latest oncology research and clinical care confidently.

The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: GSK, Merck, AbbVie, AstraZeneca, Corcept Therapeutics, Verastem, Eisai, Natera, Karyopharm Therapeutics, BioNTech

The GOG Foundation, Inc. would also like to thank our sponsors for this symposium: Gilead, Faeth Therapeutics